Marwan M. Merkhan, Eman Abdullah, Zeina Althanoon
Marwan M. Merkhan1,2*, Eman Abdullah1, Zeina Althanoon1
1College of Pharmacy, University of Mosul, Iraq.
2College of Pharmacy, Ninevah University, Iraq.
Volume - 15,
Issue - 1,
Year - 2022
Peptic ulcers are best treated by proton pump inhibitors (PPIs), however, other simple gastrointestinal (GIT) disorders should be better treated by other acid neutralizing or anti-secretory agents. Unfortunately, most GIT diseases were reported to be treated by PPIs even though non-indicated cases. The reasons might include ease availability with/without prescription, reduce patient awareness, and overprescription of PPIs by the health care professionals. This study aims to highlight the effect of these drugs on the renal function test. Patients were recruited and enrolled in the study from outpatients private clinics and plasma samples were withdrawn from control healthy, esomeprazole and omeprazole users individuals. Plasma samples were frozen for further analysis, creatinine and urea test were conducted on overall samples and the results were displayed confirming significant dysfunctioning of the renal system from PPIs use. The study concluded that creatinine and urea are higher in a patient on esomeprazole than omeprazole and the control group. The study recommends general awareness of the society about regular use of these medications unless otherwise carefully required.
Cite this article:
Marwan M. Merkhan, Eman Abdullah, Zeina Althanoon. Effect of Esomeprazole on serum creatinine and urea in patients with Peptic Ulcer. Research Journal of Pharmacy and Technology. 2022; 15(1):160-4. doi: 10.52711/0974-360X.2022.00026
Marwan M. Merkhan, Eman Abdullah, Zeina Althanoon. Effect of Esomeprazole on serum creatinine and urea in patients with Peptic Ulcer. Research Journal of Pharmacy and Technology. 2022; 15(1):160-4. doi: 10.52711/0974-360X.2022.00026 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-1-26
1. Sonagre V. Lulay P. Lingam M. Arutla S. Patel S. Kulkarni M. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research Journal of Pharmacy and Technology. 2012;5(1):20-6. doi.10.5958/0974-360X.
2. Rele RV. Tiwatane PP. Validation of Esomeprazole Magnesium Tri-hydrate in Pharmaceutical Dosage Form by RP-HPLC Method. Asian Journal of Research in Chemistry. 2018; 11(5):794-8. doi. 10.5958/0974-360X.2018.00026.4.
3. Strand DS. Kim D. Peura DA. 25 Years of Proton-Pump Inhibitors: a Comprehensive Review. Gut and Liver. 2017;11(1):27. doi.10.5009/gnl15502.
4. Chellappa S. Eerike M. Rao Konda VG. Arunachalam R. Krishnan D. Assessment of Renal Parameters in Patients on Proton Pump Inhibitors and Risk of Chronic Kidney Disease. Journal of Clinical & Diagnostic Research. 2018;12(10). doi. 10.7860/JCDR/2018/36570.12122.
5. Cook BL. Trinh NH. Li Z. Hou SS. Progovac AM. Trends in Racial-Ethnic Disparities in Access to Mental Health Care, 2004–2012. Psychiatric Services. 2017; 68(1):9-16. doi.org/10.1176/appi.ps.201500453.
6. Heidelbaugh JJ. Kim AH. Chang R. Walker PC. Overutilization of Proton-Pump Inhibitors: What the Clinician Needs to Know. Therapeutic advances in gastroenterology. 2012;5(4):219-32. doi.org/10.1177/1756283X12437358.
7. Nitin M. Reddy MU. Hasan SS. Pharmacodynamic Influence of Vitamin C and Esomeprazole on Gastro Protection in Pylorus Ligation and Aspirin Induced Ulcers in Rats. Research journal of Pharmacology and Pharmacodynamics. 2012; 4(3):4. doi.10.5958 2321-5836.
8. Patel V. Design, Development, Evaluation and Optimization of Antiulcer Delayed Release Tablets. Research Journal of Pharmacy and Technology. 2013; 6(6):669-84. doi.10.5958/0974-360X.
9. Aronson JK. Inhibiting the Proton Pump: Mechanisms, Benefits, Harms, and Questions. BMC medicine. 2016;14(1):1-4. doi.org/10.1186/s12916-016-0724-1.
10. Filion KB. Chateau D. Targownik LE. Gershon A. Durand M. Tamim H et al. Proton Pump Inhibitors and the Risk of Hospitalisation for Community-Acquired Pneumonia: Replicated Cohort Studies with Meta-Analysis. Gut. 2014; 63(4):552-8. doi.org/10.1136/gutjnl-2013-304738.
11. Kwok CS. Arthur AK. Anibueze CI. Singh S. Cavallazzi R. Loke YK. Risk of Clostridium Difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. American Journal of Gastroenterology. 2012; 107(7):1011-9. doi: 10.1038/ajg.2012.108.
12. Eusebi LH. Rabitti S. Artesiani ML. Gelli D. Montagnani M. Zagari RM. Proton Pump Inhibitors: Risks of Long‐Term use. Journal of gastroenterology and hepatology. 2017; 32(7):1295-302. doi.org/10.1111/jgh.13737.
13. Nochaiwong S. Ruengorn C. Awiphan R. Koyratkoson K. Chaisai C. Noppakun K, et al. The Association Between Proton Pump Inhibitor Use and the Risk of Adverse Kidney Outcomes: a Systematic Review and Meta-Analysis. Nephrology Dialysis Transplantation. 2018; 33(2):331-42.doi.org/10.1093/ndt/gfw470.
14. Schnoll-Sussman F. Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Current treatment options in gastroenterology. 2017; 15(1):1-9. doi.org/10.1007/s11938-017-0115-5.
15. Rodriguez-Poncelas A. Barceló MA. Saez M. Coll-de-Tuero G. Duration and Dosing of Proton Pump Inhibitors Associated with High Incidence of Chronic Kidney Disease in Population-Based Cohort. PLoS One. 2018; 13(10):e0204231. doi.org/10.1371/journal.pone.0204231.
16. Lakshmi SD. Jacob JT. Srinivas D. Satyanarayana D. Simultaneous Estimation of Naproxen and Esomeprazole by RP-HPLC and its Validation. Research Journal of Pharmacy and Technology. 2015; 8(7):1. 10.5958/0974-360X.2015.00133.X.
17. Stevens PE. Levin A. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Annals of internal medicine. 2013; 158(11):825-30. doi.org/10.7326/0003-4819-158-11-201306040-00007.
18. Muriithi AK. Leung N. Valeri AM. Cornell LD. Sethi S. Fidler ME et al. Biopsy-Proven Acute Interstitial Nephritis, 1993-2011: a Case Series. American Journal of Kidney Diseases. 2014; 64(4):558-66. doi.org/10.1053/j.ajkd.2014.04.027.
19. Savides TJ. Pratha V. Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers. Gastrointestinal endoscopy. 2001; 54(1):130-2.
20. Yang Y. George KC. Shang WF. Zeng R. Ge SW. Xu G. Proton-Pump Inhibitors Use, and Risk of Acute Kidney Injury: a Meta-Analysis of Observational Studies. Drug design, development and therapy. 2017;11:1291. doi: 10.2147/DDDT.S130568.
21. Praga M. González E. Acute Interstitial Nephritis. Kidney international. 2010;77(11):956-61. doi.org/10.1038/ki.2010.89.
22. Brewster U. Perazella M. Proton Pump Inhibitors and the Kidney: Critical Review. Clinical nephrology. 2007; 68:65-72. doi.10.5414/cnp68065.
23. Simpson IJ. Marshall MR. Pilmore H. Manley P. Williams L. Thein H et al. Proton Pump Inhibitors and Acute Interstitial Nephritis: Report and Analysis of 15 Cases. Nephrology. 2006;11(5):381-5. doi.org/10.1111/j.1440-1797.2006.00651.x.
24. Lazarus B. Chen Y. Wilson FP. Sang Y. Chang AR. Coresh J et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA internal medicine. 2016; 176(2):238-46. doi.10.1001/jamainternmed.2015.7193.
25. Xie Y. Bowe B. Li T. Xian H. Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology. 2016; 27(10):3153-63. doi.org/10.1681/ASN.2015121377.
26. Arora P. Gupta A. Golzy M. Patel N. Carter RL. Jalal K et al. Proton Pump Inhibitors are Associated with Increased Risk of Development of Chronic Kidney Disease. BMC nephrology. 2016; 17(1):1-8. doi.org/10.1186/s12882-016-0325-4.
27. Sampathkumar K. Ramalingam R. Prabakar A. Abraham A. Acute Interstitial Nephritis Due to Proton Pump Inhibitors. Indian journal of nephrology. 2013; 23(4):304. doi: 10.4103/0971-4065.114487.